Immunovia AB (publ) (IMMNOV.ST)
SEK 0.28
(3.38%)
SEK 0.28
(3.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.28 Million SEK | -88.59% |
| 2022 | 37.57 Million SEK | 12.96% |
| 2021 | 33.26 Million SEK | 0.4% |
| 2020 | 33.13 Million SEK | -12.16% |
| 2019 | 37.71 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 8.79 Million SEK | 105.16% |
| 2024 Q2 | 8.7 Million SEK | -0.99% |
| 2023 Q4 | 4.28 Million SEK | -83.7% |
| 2023 FY | 4.28 Million SEK | -88.59% |
| 2023 Q1 | 35.93 Million SEK | -4.36% |
| 2023 Q2 | 27.95 Million SEK | -22.21% |
| 2023 Q3 | 26.28 Million SEK | -5.96% |
| 2022 FY | 37.57 Million SEK | 12.96% |
| 2022 Q4 | 37.57 Million SEK | -5.76% |
| 2022 Q3 | 39.86 Million SEK | -1.28% |
| 2022 Q2 | 40.38 Million SEK | -0.89% |
| 2022 Q1 | 40.74 Million SEK | 22.5% |
| 2021 Q2 | 36.03 Million SEK | -4.04% |
| 2021 Q3 | 34.53 Million SEK | -4.16% |
| 2021 Q4 | 33.26 Million SEK | -3.69% |
| 2021 FY | 33.26 Million SEK | 0.4% |
| 2021 Q1 | 37.54 Million SEK | 13.33% |
| 2020 Q4 | 33.13 Million SEK | -3.62% |
| 2020 FY | 33.13 Million SEK | -12.16% |
| 2020 Q3 | 34.37 Million SEK | -3.37% |
| 2020 Q2 | 35.57 Million SEK | -3.46% |
| 2020 Q1 | 36.84 Million SEK | -2.31% |
| 2019 Q2 | 33.33 Million SEK | -2.56% |
| 2019 Q1 | 34.21 Million SEK | 0.0% |
| 2019 FY | 37.71 Million SEK | 0.0% |
| 2019 Q4 | 37.71 Million SEK | -0.78% |
| 2019 Q3 | 38.01 Million SEK | 14.03% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AroCell AB (publ) | - SEK | -Infinity% |
| Devyser Diagnostics AB (publ) | 74.8 Million SEK | 94.27% |
| Prostatype Genomics AB (publ) | 67 Thousand SEK | -6297.015% |
| SenzaGen AB | 1.67 Million SEK | -156.186% |
| Spermosens AB | 9.51 Million SEK | 54.965% |